As previously reported, Maxim upgraded CNS Pharmaceuticals (CNSP) to Buy from Hold with a $20 price target The company has pivoted to its oncology asset TPI-287, a blood brain barrier crossing taxane in development initially for recurrent glioblastoma, the analyst tells investors in a research note. Maxim further cites CNS Pharma’s road map for TPI-287, as well as a potential path forward with Berubicin and cash runway into the second half of 2026, as positioning the stock toward a recovery. Elevate Your ...